^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Folate receptor 1-targeted antibody-drug conjugate

    Related drugs:
    2d
    TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    luveltamab tazevibulin (STRO-002)
    7d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=289, Recruiting, AstraZeneca | N=46 --> 289
    Enrollment change • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    7d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=98, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    10d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=51, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    10d
    D8991C00001: AZD5335 vs. Mirvetuximab Soravtansine in FR?-high and AZD5335 vs. Chemotherapy in FR?-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) (2025-520466-22-00)
    P2/3, N=46, Not yet recruiting, AstraZeneca AB
    New P2/3 trial • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    13d
    Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. (PubMed, Nat Commun)
    We report a population of high FOLR1-expressing tumor-associated macrophages (CD163 + FOLR1 + ), suggesting potential on-target, off-tumor immune editing by MIRV. A composite biomarker score derived in this cohort correlates with objective response to MIRV and pembrolizumab.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FOLR1 ( Folate receptor alpha ) • CD163 (CD163 Molecule)
    |
    FOLR1 expression • FOLR1 positive
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    15d
    Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases. (PubMed, J Pathol Clin Res)
    Recently, the antibody-drug conjugate mirvetuximab soravtansine has been approved for treatment of advanced platinum-resistant high-grade serous carcinoma (HGSC)...In conclusion, these results confirm that FRα expression in HGSC and LGSC reaches similar values compared to published data, and is present in a minority of endometrial serous carcinomas. In other ovarian and endometrial tumors examined, FRα expression is absent or rare.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Elahere (mirvetuximab soravtansine-gynx)
    26d
    Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. (PubMed, J Clin Med)
    Collectively, VEGF-, PARP-, and FRα-targeted therapies have enabled more rational treatment sequencing, informed combination strategies, and personalized clinical decision-making in ovarian cancer. Ongoing efforts to define optimal sequencing, overcome acquired resistance, and refine predictive biomarkers are expected to further enhance the durability and breadth of benefit from targeted therapies and advance precision oncology in gynecologic malignancies.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    HRD • BRCA mutation
    |
    Avastin (bevacizumab) • Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)
    1m
    RAINFOL-02: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    FOLR1 expression • BRCA mutation
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    1m
    GLORIOSA: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov)
    P3, N=520, Recruiting, AbbVie | Trial completion date: Apr 2029 --> May 2032
    Trial completion date • Platinum sensitive
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    2ms
    IMGN151-1001: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov)
    P1, N=256, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=423 --> 256
    Enrollment closed • Enrollment change • First-in-human
    |
    FOLR1 ( Folate receptor alpha )
    |
    opugotamig olatansine (IMGN-151)